B
BVF Partners L.P.
+ 持有NCEL
+8.72%
3個月報酬率
$2.724
-0.156 (-5.73%)收盤時
Loading chart…
- 最高
- 2.800
- 開盤
- 2.800
- 成交量加權均價
- 2.72
- 成交量
- 11.24K
- 市值
- —
- 最低
- 2.645
- 成交金額
- 30.61K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
AI 分析 of NewcelX AG (NCEL)
買進NewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
估值指標
NewcelX AG（NCEL）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
持有 NCEL 的大戶
事件時間軸
資訊
8.507-31NewsfilterNewcelX Secures Private Placement to Advance Diabetes Therapy
- 5.007-08Newsfilter
NewcelX Appoints Diabetes Research Authority Dr. Camillo Ricordi to Advisory Board
- 8.507-08Newsfilter
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- 8.507-01Newsfilter
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- 3.506-15Newsfilter
NewcelX Publishes AstroRx® Study Results
NCEL 常見問題 —— 由 Alphio AI 解答
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ. It operates in the Healthcare sector.
NewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。